Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 26, 2015 3:53 PM ET


Company Overview of ViaCyte, Inc.

Company Overview

ViaCyte, Inc., a preclinical stage stem cell engineering company, develops and commercializes cell therapies to treat diabetes in the United States and internationally. The company develops human embryonic stem cells for Type 1 and Type 2 diabetic patients, as well as therapies based on pancreatic beta cell progenitors derived from human pluripotent stem cells. It develops insulin-producing cells from human embryonic stem cells to produce islet cells; and Encaptra, a vascularizing device that enables implanted pancreatic progenitor cells to survive and differentiate into functioning islet cells. The company was formerly known as Novocell, Inc. and changed its name to ViaCyte, Inc. in May 201...

3550 General Atomics Court

San Diego, CA 92121

United States

Founded in 1999





Key Executives for ViaCyte, Inc.

Chief Executive Officer and President
Age: 59
Vice President of Finance and Corporate Controller
Chief Development Officer and Vice President of Device Research and Development
Chief Medical Officer and Vice President of Clinical Development
Age: 61
Senior Vice President of Science & Technology
Compensation as of Fiscal Year 2015.

ViaCyte, Inc. Key Developments

ViaCyte Licenses Cell Differentiation Technology to Takara Bio Inc

ViaCyte, Inc. announced that the company has entered into a non-exclusive licensing agreement with Takara Bio, Inc. Takara will utilize certain portions of ViaCyte's cell differentiation technology to expand its stem cell product line, marketed under the Cellartis® brand. Takara will make the technology available for research purposes only, not for clinical or commercial application. The licensing agreement includes ViaCyte technology for a robust method of making definitive endoderm (DE) cells from induced pluripotent stem (iPS) cells, a necessary step in the production of a number of cell types. Takara will incorporate the technology into the kits it markets to researchers, including the Cellartis® iPS Cell to Hepatocyte Differentiation System.

ViaCyte, Inc. Presents at Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa, Oct-07-2015 11:45 AM

ViaCyte, Inc. Presents at Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa, Oct-07-2015 11:45 AM. Venue: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037, United States. Speakers: Paul K. Laikind, Chief Executive Officer and President.

ViaCyte Announces the Publication of a Report on Macroencapsulated Stem Cell-Derived Insulin-Producing Cells and the Issuance of Three Patents

ViaCyte, Inc. announced publication of a study demonstrating that insulin-producing cells created in vitro from human embryonic stem cells can mature and function after being encapsulated and implanted into an animal model. In addition, the Company announced the addition of three patents to its extensive portfolio covering its cell therapy platform. The article, entitled "Insulin-Producing Endocrine Cells Differentiated In Vitro From Human Embryonic Stem Cells Function in Macroencapsulation Devices In Vivo," is published in Stem Cells Translational Medicine. In the June 2015 issue of the same journal, ViaCyte scientists published a review article summarizing the advances in bioprocessing and scale-up that have enabled ViaCyte's VC-01 product candidate to be the first stem cell-based treatment for type 1 diabetes to enter clinical testing. The current article describes beta-like cells that have similar properties to the pluripotent stem cell-derived insulin-producing cells reported by other groups, except that ViaCyte produced populations with substantially higher endocrine cell content. The results demonstrated for the first time that nearly pure in vitro-produced endocrine cells can function in vivo. Populations comprised of up to 98% endocrine cells (and less than 2% pancreatic progenitor cells) exhibited robust glucose-responsive insulin production in a mouse model. The cells in the study were differentiated further down the beta cell lineage than the PEC-01™ pancreatic progenitor cells being tested in ViaCyte's VC-01 product candidate, which is currently in a Phase 1/2 clinical trial for treatment of type 1 diabetes. The animal study also demonstrated for the first time that when encapsulated in a device and implanted into mice, these more mature cells are capable of producing functional pancreatic beta cells. ViaCyte is also the first to show that these further differentiated cells can function in vivo following cryopreservation, a valuable process step when contemplating clinical and commercial application. In addition to demonstrating in vivo functionality, the time to functional maturation (i.e., glucose-responsive insulin production) following implantation of the more highly differentiated cells was compared to that of pancreatic progenitors. The results showed no appreciable differences between the two cell populations suggesting that engraftment and acquisition of a robust glucose response, not differentiation from progenitor cell to endocrine cell, are the rate-limiting steps following implantation. In addition to the research progress, ViaCyte continues to build its large patent portfolio with three more U.S. patents having issued since November 2014. These patents are directed to: Methods for making and enriching pancreatic endocrine type cells (U.S. Patent No. 9,045,736); Scale-up technology directed to pluripotent stem cell aggregates in suspension in a roller bottle (U.S. Patent No. 8,895,300); and Pancreatic endoderm cell cultures with an ERBB receptor tyrosine kinase activating agent (U.S. Patent No. 9,109,245). These patents bolster and further protect the Company's VC-01 product candidate and its cell therapy platform technology.

Similar Private Companies By Industry

Company Name Region
Link Medicine Corporation United States
BioCarta LLC United States
Pharmaceutical Experts, Inc. United States
Movement Disorder Technologies Inc. United States
Aixlie Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ViaCyte, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at